Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

被引:472
|
作者
Burden, DA
Osheroff, N
机构
[1] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Med Oncol, Sch Med, Nashville, TN 37232 USA
关键词
anticancer drug; catalytic cycle; DNA cleavage complex; drug mechanism; topoisomerase II;
D O I
10.1016/S0167-4781(98)00132-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays critical roles in virtually every aspect of DNA metabolism. The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a separate helix. Beyond its physiological functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers. These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme. Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme. These advances have provided novel insights into the physiological functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs. Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymatic function and pharmacological properties. Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs. 0167-4781/98/$ see front matter (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [21] LINKER INSERTION MUTAGENESIS OF DROSOPHILA TOPOISOMERASE-II - PROBING THE STRUCTURE OF EUKARYOTIC TOPOISOMERASE-II
    LEE, MP
    HSIEH, TS
    JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (02) : 436 - 447
  • [22] MECHANISM OF ACTION OF TYPE-II ANTIARRHYTHMIC DRUGS
    HARRISON, LA
    WALLACE, A
    WITTIG, J
    JOURNAL OF CLINICAL INVESTIGATION, 1972, 51 (06): : A43 - &
  • [23] A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II α
    Jensen, LH
    Renodon-Cornière, A
    Nitiss, KC
    Hill, BT
    Nitiss, JL
    Jensen, PB
    Sehested, M
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (04) : 623 - 631
  • [24] Identification of novel molecular targeted drugs for osteosarcoma and analysis of their mechanism of action
    Takagi, Satoshi
    Koike, Sumie
    Takemoto, Ai
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2023, 114 : 1743 - 1743
  • [25] MECHANISM OF ACTION OF DNA TOPOISOMERASE INHIBITORS
    BINASCHI, M
    ZUNINO, F
    CAPRANICO, G
    STEM CELLS, 1995, 13 (04) : 369 - 379
  • [26] Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme
    Shuman, S
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3): : 321 - 337
  • [27] Secondary leukemias induced by topoisomerase-targeted drugs
    Felix, CA
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3): : 233 - 255
  • [28] Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIα and β -: Distinct mode of action of two derivatives
    Krishna, ADS
    Panda, G
    Kondapi, AK
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2005, 438 (02) : 206 - 216
  • [29] Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase
    Bakshi, RP
    Galande, S
    Muniyappa, K
    CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2001, 36 (01) : 1 - 37
  • [30] A RAPID AND QUANTITATIVE MICROTITER ASSAY FOR EUKARYOTIC TOPOISOMERASE-II
    MULLER, MT
    HELAL, K
    SOISSON, S
    SPITZNER, JR
    NUCLEIC ACIDS RESEARCH, 1989, 17 (22) : 9499 - 9499